Macmillan Cancer Support is making a significant investment in Lucida Medical’s new artificial intelligence platform, Pi, with the goal of improving the speed and accuracy of prostate cancer testing. The investment of £350,100 will help in early detection and treatment, potentially reducing the number of unnecessary invasive procedures for cancer-free patients and saving time and money for the NHS.
Prostate cancer is the most common cancer in men in the UK, with over 500,000 men living with it across the country. Over 50,000 new cases are diagnosed each year, and these numbers are projected to increase. By 2040, it is estimated that there will be 1 million men living with prostate cancer in the UK. Despite common misconceptions about its harmlessness due to slower development rates for lower grades of prostate cancer, 12,000 men still die from it annually.
The Pi platform utilizes Lucida Medical’s advanced artificial intelligence training technology to identify prostate cancer from MRI scans. Preliminary analysis suggests that the software’s accuracy is comparable to that of expert radiologists. This could significantly speed up radiologists’ work and reduce the risk of missing cancers or conducting unnecessary biopsies.
Professor Evis Sala, chief medical officer and co-founder of Lucida Medical, expressed their aim to provide every radiologist with technology that can accurately identify important cancers. This would allow more patients to benefit from early detection and treatment while also reducing painful investigations for those without prostate cancer.
Dr. Antonio Rix, CEO of Lucida Medical, emphasized their commitment to working with Macmillan as a leading cancer charity that shares their vision for transforming patient perspectives using AI technology. The goal is to avoid unnecessary biopsies and have a transformative impact on both the NHS and patients.
Tanya Humphreys, chief innovation officer at Macmillan Cancer Support, highlighted how integrating AI with MRI analysis through Pi offers a level of diagnostic accuracy that could greatly improve efficiency in detecting prostate cancer.
This investment in Lucida Medical marks Macmillan Cancer Support’s second venture into its portfolio of innovation impact investments. Over two years, they plan to invest £3.5 million in start-ups developing innovative products and technologies for cancer care.
Lucida Medical will be showcasing Pi at the 2024 European Congress of Radiology where Dr. Rix will present the latest research results on the platform. Pi is available for use in both the UK and EU to support prostate cancer diagnosis.
According to sourcethis partnership between Macmillan Cancer Support and Lucida Medical has great potential to revolutionize prostate cancer diagnosis by leveraging advanced AI technology alongside traditional methods. It aims not only to improve diagnostic accuracy but also enhance patient outcomes while reducing unnecessary procedures.